Menu
Back to User profile » Dr Mengxia Li
Papers published by Dr Mengxia Li:
MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression
Liang W, Li C, Li M, Wang D, Zhong Z
OncoTargets and Therapy 2019, 12:7203-7214
Published Date: 3 September 2019
HLA-DQB1 expression on tumor cells is a novel favorable prognostic factor for relapse in early-stage lung adenocarcinoma
Zhang L, Li M, Deng B, Dai N, Feng Y, Shan J, Yang Y, Mao C, Huang P, Xu C, Wang D
Cancer Management and Research 2019, 11:2605-2616
Published Date: 1 April 2019
Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer
Ren T, Shan J, Li M, Qing Y, Qian C, Wang G, Li Q, Lu G, Li C, Peng Y, Luo H, Zhang S, Yang Y, Cheng Y, Wang D, Zhou SF
Drug Design, Development and Therapy 2015, 9:2887-2910
Published Date: 8 June 2015
Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway
Ren T, Shan J, Qing Y, Qian C, Li Q, Lu G, Li M, Li C, Peng Y, Luo H, Zhang S, Zhang W, Wang D, Zhou SF
Drug Design, Development and Therapy 2014, 8:2517-2529
Published Date: 12 December 2014
Functional analysis of tanshinone IIA that blocks the redox function of human apurinic/apyrimidinic endonuclease 1/redox factor-1
Sui J, Li M, Qian C, Wang S, Cheng Y, Chen BP, Wang D
Drug Design, Development and Therapy 2014, 8:2147-2160
Published Date: 3 November 2014